Sermorelin — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: GHRH (1-29) analogue
Reported half-life: Approximately 10–20 minutes
Routes used in the literature: Subcutaneous and intravenous
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Paediatric GH-deficiency diagnostic testing

Reported quantity: 1 µg/kg intravenously
Frequency: Single administration
Study duration: Sampling over 60–120 minutes

This is the licensed diagnostic figure recorded in the older product literature.

Adult GH-axis research protocols

Reported quantity: 0.2–0.3 mg subcutaneously per administration
Frequency: Once nightly in multi-week arms
Study duration: Commonly 12 weeks to endpoint

Nightly timing is used because it aligns with endogenous GH pulsatility.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

Sermorelin · 10 mg Vial

Sermorelin is dosed at 200 mcg–500 mcg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~ 3.33 mg/mL concentration.
Typical daily range: 200–500 µg once daily at bedtime (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 µg on a U‑100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (36–46 °F); after reconstitution, refrigerate at 2–8 °C (36–46 °F) and use within 10–14 days.

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (µg)	Units (per injection) (mL)
Weeks 1–2	200 µg (0.2 mg)	6 units (0.06 mL)
Weeks 3–4	300 µg (0.3 mg)	9 units (0.09 mL)
Weeks 5–6	400 µg (0.4 mg)	12 units (0.12 mL)
Weeks 7–8	500 µg (0.5 mg)	15 units (0.15 mL)

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size Sermorelin is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

Sermorelin · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit	200 mcg =	500 mcg =
2 mg	0.67 mg/ml	7 mcg	30 units	75 units
5 mg	1.67 mg/ml	17 mcg	12 units	30 units
10 mg	3.33 mg/ml	33 mcg	6.0 units	15 units

Unit columns use the range reported for this compound (200 mcg–500 mcg). Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 5 mg vial with 2 mL of bacteriostatic water gives 2.5 mg/mL; 0.1 mL draws 250 µg.

Open the reconstitution calculator

How to read these figures

GHRH analogues work through the pituitary, so an intact axis is a precondition in every study design.
The peptide is unstable in solution — refrigeration after reconstitution is standard practice in the literature.
Diagnostic use and multi-week research use are distinct evidence bases; do not conflate the figures.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
Geref International Study Group · J Clin Endocrinol Metab · 1996 · PMID 8772599
110 GH-deficient prepubertal children received 30 micrograms/kg GHRH(1-29) subcutaneously once daily for up to 1 year to assess growth response.
View the record
[2]
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Prakash A, Goa KL · BioDrugs · 1999 · PMID 18031173
Review summarizing sermorelin dosing regimens (typically subcutaneous nightly injections) used in diagnostic and therapeutic studies of GH deficiency.
View the record
[3]
Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Vittone J, Blackman MR, Busby-Whitehead J, et al. · J Clin Endocrinol Metab (related GHRH aging studies) · 1997 · PMID 9141536
Long-term administration of [Nle27]GHRH(1-29)-NH2 in age-advanced men and women examined endocrine and metabolic effects of chronic nightly dosing.
View the record

Search the databases yourself

Read the Sermorelin research brief

Other growth hormone compounds

AOD-9604hGH fragment 176-191 CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogue CJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blend CJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.